Introduction
Advances in metal-on-metal (MoM) hip resurfacing technology has led to improved short and long-term outcomes in selected patients (1) (2) (3) (4) (5) (6) (7) (8) . Typically, the ideal patient for hip resurfacing is a younger male with a diagnosis of primary osteoarthritis; as such, there are few studies that focus upon the results of resurfacing in patients with inflammatory arthritis. Reported advantages of hip resurfacing arthroplasty include preservation of femoral head bone, increased stability leading to lower dislocation rates, physiologic loading on the femoral head, a quicker return to activities, and improved future implant options. Disadvantages of the procedure include a technically challenging surgery, aseptic loosening and metal debris leading to adverse reactions (9, 10) . patients with RA, the estimated incidence of hip dysfunction is between 10 and 17% (15) . These patients may also develop hip disease and become symptomatic at a younger age compared to those patients with non-inflammatory aetiologies and thus procedures that preserve bone are an attractive option for these patients (14, 16, 17) .
We sought to investigate the results of hip resurfacing in patients with inflammatory arthritis because of the applicability of the procedure to this patient population, while lacking information about their surgical outcomes. The primary aim of this study was to review published literature to determine complications that may occur following hip resurfacing arthroplasty in patients with inflammatory arthritis. A secondary aim was to determine functional outcomes following hip resurfacing arthroplasty in these patients.
Methods

Protocol and search strategy
A systematic review was conducted in September 2016 in accordance with the PRISMA guidelines (18) . The search was performed in MEDLINE (PubMed/OVID), Cochrane library and Google Scholar using the search strategy found in Appendix I. A subsequent search was performed using combinations of the following terms: "hip resurfacing," "hip resurfacing arthroplasty," "metal-on-metal," "rheumatoid arthritis," "inflammatory arthritis," and "ankylosing spondylitis." Following the initial search, the references of papers that met inclusion criteria were reviewed to identify additional studies that were not identified in the initial search.
Inclusion and exclusion criteria
Studies were included if they met the following inclusion criteria: peer-reviewed retrospective or prospective trial, patient age greater than 18, a primary diagnosis of inflammatory arthritis, hip resurfacing arthroplasty was performed as the primary procedure, basic demographic data was reported, a minimum of 1 year follow-up after surgery, the number of revisions were reported, outcome measures such as the University of California at Los Angeles (UCLA) score, Harris Hip Score (HHS) and range of motion (ROM) were reported, and the studies were performed after 2006. Studies were excluded if they were not in the English literature or did not report patients with inflammatory arthritis as a subgroup.
Data extraction
Data extracted included: study type and design, primary diagnosis, mean follow-up time, type of prosthesis used, mean age at surgery, number of males and females, number of hips operated on, mean pre-and postoperative Harris Hip Score (HHS) with p value, mean pre-and postoperative UCLA score with p value, pre-and postoperative range of motion with p value, the number of revisions with reason for revision, and any complication, which included infection, dislocation, aseptic loosening, or heterotopic ossification. The methods were reviewed and any specific perioperative medication or surgical technique was noted. 
Quality assessment
Studies were graded using the Downs and Black checklist (19) . The Downs and Black checklist is a validated 27 question based checklist to assess randomised and non-randomised studies. It is scored out of 28, with each question receiving a score of 1 or 0. 1 question, item 5, can receive a maximum score of 2. Similar to Mehin et al (20) question 27 was replaced with: "Was a power analysis conducted?" with a score of 1 for yes and 0 for no.
Results
Search results
Following the initial search, 22 studies were identified. Following a subsequent search, 1 additional study was identified. 16 abstracts were screened and 3 abstracts were excluded, 2 for being author comments and 1 for not being in the English language. 13 full text articles were reviewed, 5 of which met inclusion criteria (21) (22) (23) (24) (25) (Fig. 1) . No patients were reported as lost to follow-up although Aulakh et al (22) reported 2 deaths at 5 and 7.8 years following surgery.
Study characteristics
A total of 196 hips were reported (Tab. I). 120 hips had a diagnosis of AS and seronegative spondyloarthropathy. 76 hips had a diagnosis of RA and juvenile rheumatoid arthritis. No other reports of other aetiologies of inflammatory arthritis were reported. We did not find any studies reporting on hip resurfacing in patients with systemic lupus erythematosus, likely because of the possibility of renal dysfunction, which is a contraindication. There were more males operated on than females and the mean age of all patients was 34.4 years (29.4-43.1 years). Mean follow-up time was 5.72 years (2.9-8.1 years). No randomised controlled trials were identified and the Downs-Black score ranged from 9 to 18. 
Surgical techniques, preparation, and postoperative care
All studies utilised a posterior or posterolateral approach. The study by Wisk and Amstutz (23) was the only study that reported on the class of medications that patients used prior to undergoing hip resurfacing arthroplasty. This included 10 patients taking disease modifying anti-rheumatic drugs (DMARDs), 3 patients taking nonsteroidal anti-inflammatory drugs (NSAIDs), and 3 patients taking corticosteroids. A total of 5 patients took a combination of at least 2 of the drug classes. Malhotra et al (24) excluded patients who required steroids to remain in disease remission.
3 studies reported on perioperative regimens of DMARD and indomethacin as part of their study protocol. To prevent heterotopic ossification in patients with AS, Li et al (21, 25) utilised a 100 mg indomethacin suppository starting the day prior to the procedure and continued for 3 days. The dose was then adjusted to 50 mg twice daily that was continued to the 14 th day postoperatively. These studies also administered 3800 IU of low-molecular-weight heparin, which was started 12 hours prior to surgery and continued for 10 days.
Malhotra et al (24) administered an unspecified dose of methotrexate to patients with rheumatoid arthritis. For patients with ankylosing spondylitis, 75 mg of indomethacin was administered for 2 weeks postoperatively to prevent heterotopic ossification. Lastly, all patients in this study were given 1000 mg of elemental calcium per day, 1000 IU of vitamin D per day and 70 mg of alendronate per week for at least 2 years.
Perioperative antibiotic regimens were reported in 3 studies and were administered prior to surgery and up to 5 days postoperatively (21, 24, 25) .
3 studies reported postoperative rehabilitation protocol. Li et al (21) recommended beginning functional exercises immediately after surgery as long as there was no incisional haemorrhage. Patients in this study who underwent unilateral resurfacing were restricted to 20% weight-bearing for 1 week, 50% weight-bearing for 2 weeks, and then progressed to full weight-bearing as tolerated. Patients that underwent bilateral resurfacing were restricted to functional exercises in bed for 1 week, protected walking with crutches or a walker for 1 week, and then progressed to weight-bearing as tolerated (21, 25) . Malhotra et al (24) initiated functional and weight-bearing exercises on the second postoperative day but did not specify timelines for weight-bearing restriction.
Complications
There were a total of 8 revisions, 6 patients with AS and 2 patients with RA (Tab. II). Wisk and Amstutz (23) (25) reported a revision rate of 5.0% for femoral neck fracture in that specific patient cohort. 2 infections were reported in patients with RA, 1 of which, required revision. There were no dislocations reported. In the study by Malhotra et al (24) , bilateral hip resurfacing was planned for 3 patients but was not performed on the second side due to difficulty dislocating the hip in 2 patients and lateral neck notching in the third hip. In the same study, pathology of the revision revealed generalised osteonecrosis that was believed to have occurred following the hip resurfacing.
Radiographic results
4 studies reported radiographic outcomes (Tab. III). 10 hips (5.1%) were reported to have heterotopic ossification. Brooker grade I was the most common grade, occurring in a total of 7 hips (3.6%). Malhotra et al (24) reported that all cases of heterotopic ossification occurred in patients with AS. 2 instances of radiolucency were reported, both of which occurred in zone 2 of the acetabulum (23, 24) . In both cases, the radiolucency did not progress. The preoperative diagnosis was RA in 1 patient, and the other patient's diagnosis was not disclosed. 
Functional outcomes
The studies reported a variety of functional outcomes, most commonly the UCLA and HHS. Some studies also reported on range of motion before and following hip resurfacing (Tab. IV). Nearly all studies showed increases in HHS, UCLA activity and range of motion postoperatively. Malhotra et al (24) did not calculate within group comparisons, but noted that there was a significant increase from baseline in all hips in range of motion, however, the gain in total range of motion was significantly greater in those with AS. Similarly, patients with AS had a significantly greater improvement in HHS compared to patients with RA.
Comparisons to patients undergoing total hip arthroplasty
Li et al (21) compared 38 patients undergoing hip resurfacing to 41 patients undergoing total hip arthroplasty (THA). All patients had a diagnosis of AS. Their study noted that there was no difference in improvement of UCLA activity score or HHS between groups, however, there was a significantly greater improvement in flexion-extension, abductionadduction, rotation, and total range of motion in patients who underwent hip resurfacing compared to patients who underwent THA.
Comparisons to patients with osteoarthritis
3 studies compared their functional outcomes to patients with osteoarthritis. Aulakh et al (22) compared 47 patients (54 hips) with RA to 131 patients (138 hips) with osteoarthritis. There were no significant differences in patient age or follow-up. The study reported a survival rate of 96.3% in the RA group and 97.8% in the osteoarthritis group, which was not significantly different. 2 patients in the osteoarthritis group underwent revision for aseptic loosening at 2 and 2.7 years following the initial hip resurfacing procedure. At 1 year, there was no significant difference in HHS between groups. Furthermore, at 11 years, the HHS was 90.9 in the RA group and 87.4 in the osteoarthritis group.
Li et al (25) found comparable HHS in patients with AS (n = 35, 54 hips) and osteoarthritis (n = 31, 36 hips) at final followup (93.7 ± 2.4 vs. 94.5 ± 1.9).
Wisk and Amstutz (23) compared 10 patients (13 hips) with RA and juvenile rheumatoid arthritis to 886 patients (1,061 hips) with osteoarthritis secondary to other aetiologies. The RA group was on average younger, shorter, the femoral component size was smaller, had less hips with >1 cm femoral head defect, had more cemented stems, and there was a greater proportion of patients classified as Charnley Class C. There were no revisions in the RA group but 41 revisions in the osteoarthritis group.
Discussion
This review aimed to evaluate and better understand potential complications and functional outcomes following hip resurfacing arthroplasty in patients with inflammatory arthritis. The 2 main aetiologies that were studied following hip resurfacing were AS and RA. The studies identified within this review specifically address both complications and functional outcomes following hip resurfacing arthroplasty in this patient cohort.
The most common complication that was seen following hip resurfacing arthroplasty in patients with inflammatory arthritis was femoral neck fracture, occurring in 75% of all hips that required revision and occurring between 16 weeks to 14 months following surgery. With femoral fracture as an endpoint, this occurred in 3.06% of all hips operated on. 5 of the fractures occurred in patients with AS for an incidence of 4.23% in this group. Femoral neck fracture is the most common indication for revision in patients that undergo hip resurfacing arthroplasty with an estimated prevalence of 0.9% -1.1% and a mean time to revision of 18 months following surgery (26) . This review found an increased amount of femoral neck fractures in this patient population, which occurred sooner at 34 weeks. Li et al (25) attributed the increased prevalence of femoral neck fractures in men with AS due to excess varus alignment of the femoral component. Poor bone mineral density may also contribute to increased femoral neck fractures in these patients (22) . Vitamin D deficiency is associated with rheumatologic disorders and vitamin D deficiency can contribute to pathological fractures seen in this patient population (22, 27, 28) . Only 1 study in this review screened for vitamin D levels and supplemented both vitamin D and calcium (24) . Vitamin D screening and supplementation may be an important method to adequately select patients with inflammatory arthritis to determine their eligibility for resurfacing.
2 infections were reported in patients with RA, 1 of which responded to antibiotics immediately following surgery and the other required revision 5.3 years following the initial procedure. Patients with RA have an increased risk of prosthetic joint infection following surgery (29, 30) . Kunutsor et al (30) found an increased relative risk of 1.68 (95% confidence interval [CI], 1.26-2.25) for patients who have taken steroids previously compared to patients who had never taken steroids. In this review, only 1 study reported on medication usage prior to undergoing surgery (23) . High dose corticosteroid usage is a contraindication to hip resurfacing arthroplasty but remains a critical part of management of inflammatory arthritis. The short-and long-term effects of corticosteroid and DMARD usage in patients that undergo hip resurfacing arthroplasty is not known and remains a key area of future research.
There were no dislocations reported. A commonly cited advantage of hip resurfacing arthroplasty is that it leads to a lower dislocation rate due to the larger femoral head creating a greater surface area for articulation. The lower dislocation rate may be of particular benefit to patients with AS, as the greater range of motion may prevent re-ankylosis and benefit patients with inflexible spines (21, 24) . Patients with RA also have an increased risk of dislocation following total hip arthroplasty (22, 31, 32) . Dislocation in patients with RA following total hip arthroplasty may be due to soft tissue laxity, smaller femoral head sizes, anatomic irregularity of the acetabulum, and risk of osteoporosis compared to patients with osteoarthritis (22, 31) . The ability to prevent dislocations and allow early return to active function may be a benefit to patients with inflammatory arthritis.
Hip resurfacing arthroplasty is not indicated in young women who wish to become pregnant in the future as the pregnancy related complications and adverse of metal on metal debris on the fetus are unknown. Therefore, hip resurfacing may not be a suitable alternative in a young active woman with inflammatory arthritis who wishes to become pregnant in the future.
Patients with inflammatory arthritis may present more operative challenges for the surgeon. 1 study reported on the failure of 2 patients to undergo bilateral resurfacing due to the inability to dislocate the hip. The operative plan should remain flexible as complications may arise during surgery.
This review found increases in multiple functional outcomes from baseline to include HHS, UCLA activity scores, and range of motion at the final follow-up. 2 studies showed similar outcomes compared to those patients who underwent hip resurfacing arthroplasty for osteoarthritis. These results suggest that hip resurfacing arthroplasty may provide adequate return to function for patients with inflammatory arthritis however further study is required to compare these outcomes to patients with osteoarthritis and patients that underwent total hip arthroplasty.
The main limitation of this review is the small sample size as only 5 studies were identified, none of which were randomised controlled trials. Of the studies analysed, there was a relatively small sample size in each study and the follow-up period was both highly variable and short term. Along with this, there was limited information regarding inflammatory arthritis aetiologies other than AS and RA. In addition, aggregate data was unable to be compiled across the 5 studies due to the lack of reporting similar outcome variables and distribution of the data. This review also included 2 studies by the same investigator. It is possible that some of the patients from the original study may also be included in the second study, thus introducing some selection bias. As such, the incidence of adverse events presented in this review may be underestimated. However, given the low number of studies identified in the review, it remains critical to report this information. 1 author stated that they received royalties from the resurfacing implants that were studied. Lastly, as only studies published in English were reviewed, there may be publication bias.
Conclusion
The quality of evidence reporting on patients with inflammatory arthritis that undergo hip resurfacing arthroplasty is poor. Following hip resurfacing arthroplasty, there may be an increased rate of femoral neck fractures in patients with inflammatory arthritis, especially patients with a diagnosis of ankylosing spondylitis. Despite this, hip resurfacing arthroplasty remains an attractive option because of the younger age of these patients. Furthermore, a potential advantage of hip resurfacing arthroplasty in patients with inflammatory arthritis is a lower dislocation rate. Hip resurfacing arthroplasty produces improved functional outcomes following surgery in this patient population. Larger prospective studies with a long-term follow-up are required to fully evaluate both complications and outcomes following hip resurfacing arthroplasty in patients with inflammatory arthritis. 
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